Gilda G Hillman Selected Research

Gilda G Hillman Research Topics

Disease

32	Neoplasms (Cancer) 01/2019 - 01/2003
14	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 10/2004
10	Fibrosis (Cirrhosis) 09/2017 - 08/2003
8	Lung Neoplasms (Lung Cancer) 01/2020 - 11/2011
8	Neoplasm Metastasis (Metastasis) 07/2011 - 01/2003
7	Pneumonia (Pneumonitis) 01/2020 - 10/2013
7	Carcinoma (Carcinomatosis) 05/2014 - 01/2003
6	Inflammation (Inflammations) 01/2020 - 11/2011
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 01/2004
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 04/2011
4	Radiation Injuries (Radiation Sickness) 09/2017 - 11/2011
3	Lung Injury 01/2020 - 12/2015
3	Lymphatic Metastasis 06/2007 - 07/2006
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 09/2017
2	Residual Neoplasm 05/2014 - 11/2011
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2020
1	Radiation Fibrosis Syndrome (Radiation Fibrosis) 09/2017
1	Ischemia 09/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 09/2017
1	Myocardial Infarction 09/2017
1	Heart Failure 09/2017
1	Hypertrophy 01/2015
1	Esophagitis 01/2015
1	Glioma (Gliomas) 10/2014
1	Hypertension (High Blood Pressure) 10/2014
1	Fatigue 10/2014
1	Vascular System Injuries 05/2014
1	Weight Loss (Weight Reduction) 05/2014
1	Alopecia (Baldness) 11/2013
1	Hemorrhage 11/2011
1	Hypoxia (Hypoxemia) 06/2007
1	Necrosis 10/2004

Drug/Important Bio-Agent (IBA)

21	IsoflavonesIBA 01/2020 - 04/2006
7	GenisteinIBA 06/2010 - 10/2004
6	Proteins (Proteins, Gene)FDA Link 03/2007 - 10/2003
3	AntioxidantsIBA 01/2019 - 12/2007
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2017 - 05/2003
3	NF-kappa B (NF-kB)IBA 04/2009 - 04/2006
3	Histocompatibility Antigens Class IIIBA 06/2004 - 04/2004
2	VaccinesIBA 01/2017 - 06/2004
2	Cancer VaccinesIBA 01/2017 - 05/2003
2	Sunitinib (Sutent)FDA Link 10/2014 - 09/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2014 - 04/2009
2	Hormones (Hormone)IBA 05/2012 - 06/2010
2	Transcription Factors (Transcription Factor)IBA 07/2011 - 04/2009
2	daidzeinIBA 06/2010 - 03/2007
2	glyciteinIBA 06/2010 - 03/2007
2	Peptides (Polypeptides)IBA 06/2004 - 05/2004
2	Histocompatibility Antigens Class IIBA 06/2004 - 05/2004
2	AntigensIBA 05/2004 - 04/2004
2	EpitopesIBA 05/2004 - 04/2004
2	CytokinesIBA 01/2004 - 08/2003
2	Interleukin-2 (IL2)IBA 10/2003 - 08/2003
1	Complement System Proteins (Complement)IBA 09/2017
1	TG4010IBA 01/2017
1	CollagenIBA 01/2015
1	Transaminases (Aminotransferases)IBA 10/2014
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2014
1	Axitinib (AG 013736)IBA 05/2014
1	Angiogenesis InhibitorsIBA 05/2014
1	Androgen Receptors (Androgen Receptor)IBA 05/2012
1	TabletsIBA 11/2011
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 07/2011
1	Antineoplastic Agents (Antineoplastics)IBA 07/2011
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 07/2011
1	EnzymesIBA 07/2011
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 09/2009
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 09/2009
1	PhytochemicalsIBA 12/2007
1	Therapeutic UsesIBA 06/2007
1	EndonucleasesIBA 03/2007
1	Cyclin B1IBA 04/2006
1	invariant chain (Ii-Key)IBA 02/2005
1	HLA-DR Antigens (HLA-DR)IBA 05/2004
1	MHC class II transactivator proteinIBA 10/2003
1	Hydroxyeicosatetraenoic Acids (HETE)IBA 01/2003
1	Arachidonate 12-Lipoxygenase (12 Lipoxygenase)IBA 01/2003
1	LipidsIBA 01/2003
1	AcidsIBA 01/2003
1	Arachidonic Acid (Vitamin F)IBA 01/2003

Therapy/Procedure

25	Radiotherapy 01/2020 - 05/2003
9	Therapeutics 01/2017 - 08/2003
3	Injections 01/2017 - 05/2003
3	Immunotherapy 06/2004 - 10/2003
2	Chemoprevention 01/2012 - 12/2007
2	Drug Therapy (Chemotherapy) 01/2012 - 09/2009